MARKET

ARTL

ARTL

Artelo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.200
-0.080
-6.25%
Closed 16:00 06/01 EDT
OPEN
1.260
PREV CLOSE
1.280
HIGH
1.260
LOW
1.200
VOLUME
65.58K
TURNOVER
--
52 WEEK HIGH
5.00
52 WEEK LOW
0.6100
MARKET CAP
4.11M
P/E (TTM)
-0.9690
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARTL stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.

EPS

ARTL News

More
Maxim Group Downgrades Artelo Biosciences to Hold
Maxim Group analyst Jason McCarthy downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.
Benzinga · 05/13 15:36
Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal
GlobeNewswire · 05/12 14:30
Independent Chairperson of the Board Connie Matsui Just Bought 278% More Shares In Artelo Biosciences, Inc. (NASDAQ:ARTL)
Simply Wall St. · 05/06 14:09
Artelo Biosciences EPS beats by $0.15
seekingalpha · 04/14 17:32
Artelo Biosciences Q2 EPS $(0.400)
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.400) per share.
Benzinga · 04/14 12:33
Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update
GlobeNewswire · 04/14 12:30
Artelo Biosciences to Present at the Spring Investor Summit on March 25th
ACCESSWIRE · 03/23 14:00
Here's Why We're A Bit Worried About Artelo Biosciences's (NASDAQ:ARTL) Cash Burn Situation
Simply Wall St. · 03/02 14:07

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About ARTL

Artelo Biosciences, Inc. is a biopharmaceutical company. The Company is focused on licensing, developing and commercializing treatments intended to modulate the endocannabinoid system (ECS). It develops and commercializes ethical pharmaceutical products that provide physicians access to the therapeutic potential of cannabinoid therapeutics and other modulators of the ECS for their patients. Its pipeline includes ART12.11, ART26.12 and ART27.13. The Company is developing ART12.11 for targeting the development in Inflammatory Bowel Disease (IBD), stroke and rare/orphan diseases. ART26.12 is its endocannabinoid transport protein (FABP5) inhibitor for treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain. ART27.13 is being developed for cancer. The Company also intends to develop a formulation suitable for treatment of anorexia/weight loss associated with cancer (cachexia).
More

Webull offers kinds of Artelo Biosciences Inc stock information, including NASDAQ:ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions.